Pfizer, AstraZeneca and J&J Take Issue With FDA’s List of Companies Withholding Drug Samples

When seven biopharma executives were asked by senators in February whether they had intentionally blocked generic competition, all of them said no.

But several of the companies’ products were included in a recently updated list from the US Food and Drug Administration (FDA) showing inquiries to the agency from prospective generic applicants indicating that they would like to develop a generic, but are unable to obtain the necessary samples of the reference listed drug (RLD).